---
title: "Ultragenyx Pharmaceutical (RARE) Gets a Buy from Piper Sandler"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285537982.md"
description: "Piper Sandler analyst Allison Bratzel has maintained a Buy rating on Ultragenyx Pharmaceutical (RARE) with a price target of $68.00. The analyst consensus for the company is a Strong Buy, with an average price target of $52.56. Bratzel has an average return of 45.1% and a 62.66% success rate on her stock recommendations, focusing on the Healthcare sector."
datetime: "2026-05-07T11:14:06.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285537982.md)
  - [en](https://longbridge.com/en/news/285537982.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285537982.md)
---

# Ultragenyx Pharmaceutical (RARE) Gets a Buy from Piper Sandler

Piper Sandler analyst Allison Bratzel maintained a Buy rating on Ultragenyx Pharmaceutical today and set a price target of $68.00.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Bratzel covers the Healthcare sector, focusing on stocks such as Cogent Biosciences, Ardelyx, and Travere Therapeutics. According to TipRanks, Bratzel has an average return of 45.1% and a 62.66% success rate on recommended stocks.

Currently, the analyst consensus on Ultragenyx Pharmaceutical is a Strong Buy with an average price target of $52.56.

### Related Stocks

- [RARE.US](https://longbridge.com/en/quote/RARE.US.md)
- [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [PIPR.US](https://longbridge.com/en/quote/PIPR.US.md)
- [COGT.US](https://longbridge.com/en/quote/COGT.US.md)
- [ARDX.US](https://longbridge.com/en/quote/ARDX.US.md)
- [TVTX.US](https://longbridge.com/en/quote/TVTX.US.md)

## Related News & Research

- [LifeSci Capital Sticks to Their Buy Rating for Tenax Therapeutics (TENX)](https://longbridge.com/en/news/286648286.md)
- [14:05 ETLupin Receives Tentative Approval from U.S. FDA for Revefenacin Inhalation Solution](https://longbridge.com/en/news/286805922.md)
- [Enanta Pharma's RSV Bet And Immunology Ambitions](https://longbridge.com/en/news/286895623.md)
- [Eton Pharmaceuticals Q1 product sales rise driven by portfolio expansion](https://longbridge.com/en/news/286461579.md)
- [Roth MKM Sticks to Their Buy Rating for Capricor Therapeutics (CAPR)](https://longbridge.com/en/news/286497683.md)